Current Development Stage: Hit-to-lead
CARB-X Investment: Initial investment of up to $3.2m with potential options payments up to $11.4m
Initial CARB-X Investment Date: September 1, 2019
CARB-X Investment: Initial investment of up to $3.2m with potential options payments up to $11.4m
Initial CARB-X Investment Date: September 1, 2019
Location: United States
Employees: 11-50
Total raised: $562.04K
Investors 1
| Date | Name | Website |
| - | CARB-X | carb-x.org |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.08.2026 | - | $562.04K | - |
Mentions in press and media 7
| Date | Title | Description |
| 17.08.2026 | TAXIS Pharmaceuticals Receives NIH SBIR Grant to Advance Development of Novel Antibiotic Class for Clostridioides difficile Infections | Grant marks the company's third NIH SBIR award in just over two years and supports development of a narrow-spectrum investigational therapy targeting hypervirulent C. difficile strains. MIAMI, Aug. 17, 2026 /PRNewswire-PRWeb/ -- TAXIS Pharm... |
| 26.05.2026 | TAXIS Pharmaceuticals to Present Preclinical Data on Two Investigational Antibiotic Candidates at Upcoming American Society for Microbiology Conference | TAXIS will present preclinical data from two investigational antibiotic development programs addressing urgent AMR threats. MIAMI, May 26, 2026 /PRNewswire-PRWeb/ -- TAXIS Pharmaceuticals, a clinical-stage company developing investigational... |
| 12.05.2026 | TAXIS Pharmaceuticals Announces Publication of Preclinical Data on Investigational Efflux Pump Inhibitor TXA11114 in journal Antibiotics | TXA11114 is an investigational indole carboxamide efflux pump inhibitor MIAMI, May 12, 2026 /PRNewswire-PRWeb/ -- TAXIS Pharmaceuticals, a clinical-stage company developing investigational anti-resistance therapies to address antimicrobial ... |
| 15.07.2025 | TAXIS Pharmaceuticals Earns FDA QIDP Designation for TXA14007, an Investigational Efflux Pump Inhibitor (EPI) to Combat Antibiotic-Resistant Pneumonia | TAXIS logo TAXIS Pharmaceuticals has received an FDA QIDP designation for TXA14007, its investigational efflux pump inhibitor (EPI) in combination with levofloxacin for the treatment of hospital-acquired pneumonia (HAP) and ventilator assoc... |
| 25.06.2025 | TAXIS Pharmaceuticals Names Joe DePinto, MBA and Frank Carlo Pasqualone, MBA to Its Board of Directors | TAXIS logo TAXIS Pharmaceuticals has named two industry professionals with extensive biopharma experience, Joeseph DePinto, MBA, and Frank Carlo Pasqualone, MBA, to its Board of Directors. MIAMI, June 25, 2025 /PRNewswire-PRWeb/ -- TAXIS Ph... |
| 21.04.2025 | Dr. Ajit Parhi, Chief Scientific Officer of TAXIS Pharmaceuticals, Invited to Speak at Multidrug Efflux System Gordon Research Conference | Ajit Parhi, PhD Dr. Parhi will present information on the company's Efflux Pump Inhibitors at the prestigious, invitation-only meeting MIAMI, April 21, 2025 /PRNewswire-PRWeb/ -- TAXIS Pharmaceuticals, a clinical stage company at the forefr... |
| 01.05.2024 | TAXIS Pharmaceuticals Announces $2.67 Million NIH Grant to Advance Research and Development of Combination Therapy to Combat Antibiotic-Resistant Pneumonia | TAXIS Pharmaceuticals TAXIS Pharmaceuticals' investigational efflux pump inhibitors have been shown to restore potency of FDA-approved antibiotics in animal studies. NORTH BRUNSWICK, N.J., May 1, 2024 /PRNewswire-PRWeb/ -- TAXIS Pharmaceuti... |